Drug intelligence / Profile preview

PP4001

Development stage: Phase 2
Lead developer: Pinnacle Biologics
Modality: Small Molecules
Administration: Oral (based On Dosing Schedule Described As "twice Daily" Tablets/capsules)[3][7]

Overview

PP4001 is a small molecule drug developed as a urinary analgesic for the treatment of pain and burning during urination associated with uncomplicated urinary tract infections (UTIs) and dysuria. It was investigated in phase 2 clinical trials to assess its efficacy and safety compared to placebo in alleviating symptoms such as burning during urination, pain, and increased frequency of urination. The drug was not approved by the US FDA and its development has been discontinued. The precise mechanism of action remains undefined or unreported in public sources[4][7].

Beyond the preview

Go deeper on PP4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PP4001.

Explore the full profile